Zobrazeno 71 - 80
of 236
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Francesca de Santis, Salvatore Pece, Pier Paolo Di Fiore, Filippo de Marinis, Antonio Passaro, Manuela Vecchi, Micol Tillhon, Giovanni Bertalot, Flavia Troglio, Lorenzo Spaggiari, Simona Pessina, Giuseppe Viale, Massimo Barberis, Elisa Dama, Fabrizio Bianchi, Patrizia Dell'Orto
Publikováno v:
Oncotarget
// Elisa Dama 1, 2 , Micol Tillhon 1 , Giovanni Bertalot 1 , Francesca de Santis 1, 8 , Flavia Troglio 1, 9 , Simona Pessina 3 , Antonio Passaro 4 , Salvatore Pece 1, 5 , Filippo de Marinis 4 , Patrizia Dell’Orto 3 , Giuseppe Viale 3, 5 , Lorenzo S
Autor:
Edward B. Garon, Mary O'Brien, Massimo Barberis, Paolo Antonio Ascierto, Cesare Gridelli, Filippo de Marinis, Francesca Casaluce, Assunta Sgambato, Enriqueta Felip, Vali Papadimitrakopoulou, Suresh Senan
Publikováno v:
Gridelli, C, Ascierto, P A, Barberis, M C P, Felip, E, Garon, E B, O'brien, M, Senan, S, Casaluce, F, Sgambato, A, Papadimitrakopoulou, V & De Marinis, F 2016, ' Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology ', Expert Opinion on Biological Therapy, vol. 16, no. 12, pp. 1479-1489 . https://doi.org/10.1080/14712598.2016.1234602
Expert Opinion on Biological Therapy, 16(12), 1479-1489. Taylor and Francis Ltd.
Expert Opinion on Biological Therapy, 16(12), 1479-1489. Taylor and Francis Ltd.
The potential long term survival gain, related to immune adaptability and memory, the potential activity across multiple tumour types through targeting the immune system, and the opportunity for combinations offered by the unique mechanism of actions
Autor:
Takashi Seto, Egbert F. Smit, Li Zhang, Thomas Schmelter, Filippo de Marinis, Yi-Long Wu, Carol Peña, Luis Paz-Ares, Erszébet Juhász, Osvaldo Rudy Aren, Silvia Novello, Heather A. Wakelee, Vera Hirsh, Yan Sun, Teng Jin Ong, James Chih-Hsin Yang, Tony Mok
Publikováno v:
Journal of Thoracic Oncology. 10(12):1745-1753
Introduction Sorafenib monotherapy has shown benefits in phase II trials as third-/fourth-line treatment in patients with non-small-cell lung cancer (NSCLC). Methods The phase III, multinational, double-blind, placebo-controlled Monotherapy admInistr
Autor:
Alvaro Leone, Filippo de Marinis, Rita Gasbarra, Paolo Graziano, Giuseppe Pelosi, Stefano De Santis, Bruno Gori, Rita Migliorino
Publikováno v:
Journal of Clinical Oncology. 33:e115-e118
Autor:
Monette Villalobos, Filippo de Marinis, David R. Spigel, Dolores Isla, Ida Berglin Enquist, Simonetta Mocci, Yu Deng, Jacek Jassem, Tibor Csőszi, See Phan, Gongyan Chen, Xiaohui Wen, Toyoaki Hida, Hina Patel, Jacques Cadranel, Diego Cortinovis, Giuseppe Giaccone, Roy S. Herbst, Hiroshi Kuriki, Konstantinos N. Syrigos
Publikováno v:
Journal of Clinical Oncology. 38:e21623-e21623
e21623 Background: IMpower110 evaluated atezo mono in PD-L1–selected, chemo-naive patients (pts) with nonsquamous (nsq) or squamous (sq) NSCLC. At the interim analysis, IMpower110 met its primary OS endpoint, with a statistically significant and cl
Autor:
Roy S. Herbst, Hiroshi Kuriki, Megan Chen, Lucia Bonomi, See Phan, Ioannis Boukovinas, Giuseppe Giaccone, Filippo de Marinis, Cristina-Marinela Oprean, David R. Spigel, Kimberly Komatsubara, Young-Chul Kim, Simonetta Mocci, Jacek Jassem, Takayasu Kurata, Yu Deng, Yvonne Summers, Aleksandra Szczesna
Publikováno v:
Publons
9594 Background: IMpower110 (NCT02409342) evaluated atezo (anti–PD-L1) monotherapy as 1L treatment in PD-L1–selected patients (pts) with metastatic NSCLC and met its primary endpoint with statistically significant and clinically meaningful OS ben
Autor:
Federico Cappuzzo, Joachim Widder, Stéphanie Peeters, Esther G.C. Troost, Fiona H Blackhall, Ben J. Slotman, Filippo de Marinis, José Belderbos, Raffaele Califano, Markus Glatzer, Fiona McDonald, L. Arés, Pilar Garrido, Silvia Novello, Corinne Faivre-Finn, Paul Van Houtte, Martin Reck, Dirk De Ruysscher, Benjamin Besse, Cécile Le Péchoux, Christoph Pöttgen, Martin Früh, Sara Ramella, Enriqueta Felip, Paul Martin Putora, Rafal Dziadiuszko, Mary O’ Brien, Virginie Westeel, Françoise Mornex, Ursula Nestle
Publikováno v:
Radiotherapy and Oncology. 141:332
The publisher regrets that in the abovementioned article, an author name was listed incorrectly. The correct author listing is presented above. The publisher would like to apologise for any inconvenience caused.
Publikováno v:
Chinese Clinical Oncology. 8:S1-S1
Around 3–7% of patients with non-small cell lung cancer (NSCLC) have a translocation in the gene for anaplastic lymphoma kinase (ALK) (1). Since the first report of ALK detection in NSCLC in 2007, the prognosis and the treatment landscape has been
Autor:
Filippo de Marinis, Alessandra Sacco, Rita Chiari, Giovanna Finocchiaro, Nicola Normanno, Federico Cappuzzo, Laura Giannetta, Ciro Battiloro, Raffaella Pasquale, Alessandro Morabito, Libero Ciuffreda, Marcello Tiseo, Maria Carmela Piccirillo, Roberta Buosi, Paolo Bidoli, Luisa Foltran, Riziero Esposito Abate, Gianpiero Fasola, G. Romano, Antonio Frassoldati
Publikováno v:
Cancers
Volume 11
Issue 10
Cancers, Vol 11, Iss 10, p 1431 (2019)
Volume 11
Issue 10
Cancers, Vol 11, Iss 10, p 1431 (2019)
The ICARUS trial is a phase II, open label, multicenter, single arm study conducted to investigate the efficacy, safety, and tolerability of a rechallenge treatment with the first-generation tyrosine kinase inhibitor (TKI) gefitinib in advanced non-s
Autor:
Rodryg Ramlau, Annamaria Zimmermann, Carla Visseren-Grul, Gary Middleton, Bárbara Parente, Jean-Louis Pujol, William J. John, Luis Paz-Ares, Belen San Antonio, Nadia Chouaki, Martin Reck, Thierry Pieters, Cesare Gridelli, Filippo de Marinis
Publikováno v:
Current Medical Research and Opinion
Current Medical Research and Opinion, Taylor & Francis, 2018, 34 (5), pp.865-871. ⟨10.1080/03007995.2018.1439462⟩
Current Medical Research and Opinion, Taylor & Francis, 2018, 34 (5), pp.865-871. ⟨10.1080/03007995.2018.1439462⟩
International audience; OBJECTIVES:To assess the effect of long-term pemetrexed maintenance therapy on patients' renal function.METHODS:In the PARAMOUNT phase III trial (NCT 00789373), pemetrexed was compared with placebo as maintenance treatment in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69537639f6b34c17f7fa049169f2540a
https://hal.umontpellier.fr/hal-02290874
https://hal.umontpellier.fr/hal-02290874